Diglycolamine → 4-[4-(2-Amino-pyrimidin-5-yl)-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl]-N-[2-(2-hydroxy-ethoxy)-ethyl]-benzamide
반응식
COC1C=CC(C[N:8](CC2C=CC(OC)=CC=2)[C:9]2[N:14]=[CH:13][C:12]([C:15]3[C:16]4[CH2:29][CH2:28][N:27]([C:30]5[CH:38]=[CH:37][C:33]([C:34](O)=[O:35])=[CH:32][CH:31]=5)[C:17]=4[N:18]=[C:19]([N:21]4[CH2:26][CH2:25][O:24][CH2:23][CH2:22]4)[N:20]=3)=[CH:11][N:10]=2)=CC=1.[NH2:50][CH2:51][CH2:52][O:53][CH2:54][CH2:55][OH:56]>>[NH2:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[C:16]3[CH2:29][CH2:28][N:27]([C:30]4[CH:31]=[CH:32][C:33]([C:34]([NH:50][CH2:51][CH2:52][O:53][CH2:54][CH2:55][OH:56])=[O:35])=[CH:37][CH:38]=4)[C:17]=3[N:18]=[C:19]([N:21]3[CH2:26][CH2:25][O:24][CH2:23][CH2:22]3)[N:20]=2)=[CH:11][N:10]=1참가 물질
3
반응물 2
생성물 1
실험 절차
Using 4-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-benzoic acid (38 mg) obtained in Step A in Example 1-D-19 and 2-(2-aminoethoxy)ethanol (6 μl) instead of 3-(aminomethyl)pyridine, in the same manner as Step B in Example 1-D-19, 4-(4-{2-[bis-(4-methoxy-benzyl)-amino]-pyrimidin-5-yl}-2-morpholin-4-yl-5,6-dihydro-pyrrolo[2,3-d]pyrimidin-7-yl)-N-[2-(2-hydroxy-ethoxy)-ethyl]-benzamide was obtained, and further PMB group was removed according to the above Deprotection method 3, to obtain the desired compound (D-179) as a colorless powder (3 mg, 10%).